The stock of Organogenesis Holdings Inc (NASDAQ:ORGO) last traded at $3.06, down -42.70% from the previous session.
ORGO stock price is now -35.52% away from the 50-day moving average and -14.34% away from the 200-day moving average. The market capitalization of the company currently stands at $388.16M.
With the price target of $5, Lake Street recently initiated with Buy rating for Organogenesis Holdings Inc (NASDAQ: ORGO). On February 07, 2024, Cantor Fitzgerald recently initiated its ‘Overweight’ rating on the stock quoting a target price of $5, while ‘Morgan Stanley’ rates the stock as ‘Equal-Weight’
In other news, Driscoll Michael Joseph, Director bought 25,000 shares of the company’s stock on Mar 04 ’25. The stock was bought for $127,000 at an average price of $5.08. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 04 ’25, Director Driscoll Michael Joseph sold 25,000 shares of the business’s stock. A total of $127,535 was realized by selling the stock at an average price of $5.10. This leaves the insider owning 166,879 shares of the company worth $0.51 million. A total of 49.24% of the company’s stock is owned by insiders.
During the past 12 months, Organogenesis Holdings Inc has had a low of $2.21 and a high of $6.71. As of last week, the company has a debt-to-equity ratio of 0.12, a current ratio of 4.12, and a quick ratio of 3.67.
The net profit margin was -4.06% and return on equity was -4.92% for ORGO. The company reported revenue of $86.69 million for the quarter, compared to $109.98 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -21.17 percent.
